BLAINJECTIONINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO QVANTIG is a subcutaneous formulation of nivolumab, a PD-1 checkpoint inhibitor, combined with recombinant human hyaluronidase (NVHY) to enable rapid subcutaneous delivery. It represents a patient-convenience enhancement to the established intravenous nivolumab franchise by reducing infusion time and site burden. The fixed-dose combination maintains the immunooncology mechanism of action while improving administration accessibility.
Growth
As a newly approved formulation in the growth phase, commercial teams will scale patient education and payer access strategies to drive subcutaneous nivolumab adoption.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Bristol Myers Squibb is hiring 1 role related to this product
Worked on OPDIVO QVANTIG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.